P
Philippe Lagacé-Wiens
Researcher at University of Manitoba
Publications - 135
Citations - 5628
Philippe Lagacé-Wiens is an academic researcher from University of Manitoba. The author has contributed to research in topics: Meropenem & Broth microdilution. The author has an hindex of 36, co-authored 126 publications receiving 4614 citations. Previous affiliations of Philippe Lagacé-Wiens include Manitoba Health & Public Health Agency of Canada.
Papers
More filters
Journal ArticleDOI
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
George G. Zhanel,George G. Zhanel,Christopher D. Lawson,Heather J. Adam,Heather J. Adam,Frank Schweizer,Sheryl A. Zelenitsky,Philippe Lagacé-Wiens,Andrew J Denisuik,Ethan Rubinstein,Ethan Rubinstein,Alfred S. Gin,Alfred S. Gin,Daryl J. Hoban,Daryl J. Hoban,Joseph P. Lynch,James A. Karlowsky,James A. Karlowsky +17 more
TL;DR: Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftAZidime alone.
Journal ArticleDOI
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel,George G. Zhanel,Phillip Chung,Heather J. Adam,Heather J. Adam,Sheryl A. Zelenitsky,Andrew J Denisuik,Frank Schweizer,Philippe Lagacé-Wiens,Ethan Rubinstein,Ethan Rubinstein,Alfred S. Gin,Alfred S. Gin,Andrew Walkty,Andrew Walkty,Daryl J. Hoban,Daryl J. Hoban,Joseph P. Lynch,James A. Karlowsky +18 more
TL;DR: Time-kill experiments and animal infection models have demonstrated that the pharmacokinetic–pharmacodynamic index that is best correlated with ceftolozane’s in vivo efficacy is the percentage of time in which free plasma drug concentrations exceed the minimum inhibitory concentration of a given pathogen, as expected of β-lactams.
Journal ArticleDOI
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
George G. Zhanel,Mel DeCorby,Nancy M. Laing,Barb Weshnoweski,Ravi Vashisht,Franil Tailor,Kim Nichol,Aleksandra Wierzbowski,Patricia J. Baudry,James A. Karlowsky,Philippe Lagacé-Wiens,Andrew Walkty,Melissa McCracken,Michael R. Mulvey,J. Johnson,Daryl J. Hoban +15 more
TL;DR: A multidrug-resistant (MDR) phenotype (resistance to three or more of the following drugs: cefepime, piperacillin-tazobactam, meropenem, amikacin or gentamicin, and ciprofloxacin) occurred frequently in P. aeruginosa but uncommonly in E. coli.
Journal ArticleDOI
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
George G. Zhanel,Divna Calic,Frank Schweizer,Sheryl A. Zelenitsky,Heather J. Adam,Philippe Lagacé-Wiens,Ethan Rubinstein,Alfred S. Gin,Daryl J. Hoban,James A. Karlowsky +9 more
TL;DR: Clinical trials involving patients with complicated skin and skin structure infections (cSSSIs) have demonstrated that all three agents are as efficacious as comparators, and the most common adverse effects reported with dalbavancin use included nausea, diarrhoea and constipation.
Journal ArticleDOI
Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations
George G. Zhanel,Courtney K. Lawrence,Heather J. Adam,Frank Schweizer,Sheryl A. Zelenitsky,Michael A. Zhanel,Philippe Lagacé-Wiens,Andrew Walkty,Andrew J Denisuik,Alyssa R Golden,Alfred S. Gin,Daryl J. Hoban,Joseph P. Lynch,James A. Karlowsky +13 more
TL;DR: The addition of relebactam significantly improves the activity of imipenem against most species of Enterobacteriaceae depending on the presence or absence of β-lactamase enzymes, and the pharmacokinetics of vaborbact am are described by a two-compartment, linear model and do not appear to be altered by the co-administration of imIPenem and meropenem, respectively.